It would be preferred if the body's immune system ... of cytotoxic T cells (CTL) or CD8+ T killer cells that proliferate and kill target cells that specifically represent the antigens presented by APC...
RARITAN, N.J., May 15, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced that data related to three Janssen Oncology compounds have been selected for presentation at the 49 ...
Two to 3 exchanges are required to reduce the IgM levels by 30%-60% ... Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res. Jan 1 2009;15(1):355-60. [Medline]. Laszlo D. Ri...
Janssen Oncology Data to be Presented at 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, Including ZYTIGA®, Ibrutinib and Daratumumab Data Note: This release corresponds to ASCO abs...
and in patients with Waldenstrom's macroglobulinemia (WM). Janssen and Pharmacyclics, Inc. are co-developing and will co-commercialize ibrutinib. Enacted as part of the 2012 FDA Safety and Innovation ...
The target for review of new drug application (NDA) submissions is now 12 months for standard submissions and eight months for priority reviews ... range of cancer types. The FDA promises to act on a ...
It would be preferred if the body's immune system could be incited to exhibit a positive ... involved in the prevention of various infections. "In a cellular immune response, on recognizing the APC di...
Two to 3 exchanges are required to reduce the IgM levels by 30%-60% ... Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res. Jan 1 2009;15(1):355-60. [Medline]. Laszlo D. Ri...
and in patients with Waldenstrom's macroglobulinemia (WM). Janssen and Pharmacyclics, Inc. are co-developing and will co-commercialize ibrutinib. Enacted as part of the 2012 FDA Safety and Innovation ...
About Waldenstrom's Macroglobulinemia Waldenstrom's macroglobulinemia is rare type of lymphoma. The disease begins with a malignant change to the B-cell during its maturation so that it continues to r...
The target for review of new drug application (NDA) submissions is now 12 months for standard submissions and eight months for priority reviews ... range of cancer types. The FDA promises to act on a ...
The target for review of new drug application (NDA) submissions is now 12 months for standard submissions and eight months for priority reviews ... range of cancer types. The FDA promises to act on a ...
SUNNYVALE, Calif., May 1, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") PCYC today reported financial results and recent developments for its three months ended March 31, 2013. Financial Re...
Enacted as part of the 2012 FDA Safety and Innovation Act (FDASIA), Breakthrough Therapy Designation is intended to expedite the development and review time for a potential new medicine "to treat a se...
The opinions expressed in WebMD User-generated content areas like communities, review, ratings, or blogs are solely those of the User ... and two types of non-Hodgkin’s lymphoma: mantle cell lymphom...
For those who might not know, longtime Internet and tech figure Steve Kirsch (pictured here) wrote a blog a few weeks ago about a recent ... In other words, I’m going to die soon. Today, [Waldenstro...
